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Cationic polymers such as polyallylamine (PAA) having primary amino groups are poor transfection 
agents and possess a high cytotoxicity index when used without any chemical modification. In this study, 
PAA was modified with cholesterol in order to improve transfection efficiency and to reduce cytotoxicity. 
PAA polymers with molecular weights of 15 and 65 kDa were selected and grafted with cholesterol at 
percentages of 5, 10, 15, 30, and 50. After purification, the efficacy of the synthetic vectors was evaluated 
in terms of DNA condensation using the ethidium bromide test, buffering capacity, particle size, zeta 
potential, transfection efficiency, and cytotoxicity assay in Neuro2A cell lines. According to the ethidium 
bromide test, these vectors can condense DNA at moderate and high carrier to plasmid (C/P) ratios. 
The buffering capacity of the prepared vector in both molecular weights was less than unmodified PAA. 
Particle size measurements demonstrated that modified PAAs were able to form nanoparticles ranging in 
size from 125 to 530 nm. The vectors based on PAA 15 kDa demonstrated a better transfection efficiency 
than the vectors made of PAA 65 kDa. Cytotoxicity studies showed that toxicity of all vectors was less 
than PAA. Some cholesterol modified polymers composed of PAA (15 kDa) were suitable vectors for 
gene delivery with low cytotoxicity.
Keywords: Cholesterol/ efficiency. Gene delivery. Non-viral vectors/evaluation. Polyallylamine 
Transfection efficiency. Cytotoxicity/study.
INTRODUCTION
Research in recent years has witnessed major 
concern about gene therapy providing novel approaches to 
the treatment of many diseases caused by genetic disorders 
(Guo et al., 2008). The delivery of nucleic acids to target 
cells and tissues, despite all achieved advances, still 
remains challenging (Li, Huang, 2000; Chesnoy, Huang, 
2000). Specifically, gene therapy pursues the development 
of non-toxic effective gene carrier encapsulating and 
carrying foreign genetic materials into specific cell types 
including cancerous cells (El-Aneed, 2004).
Gene delivery carriers are generally divided into 
two major groups named viral and non-viral vectors (Liu, 
Huang, 2002). Each of these vectors demonstrates its 
own advantages and drawbacks (Cusack, Tanabe, 2002). 
Many deficiencies in several areas including the induction 
of host inflammatory and immune response are reported 
for viral vectors, though they provide high gene delivery 
efficiency (Tros-de-Ilarduya, Sun, Duzgunes, 2010). Non-
viral vectors, especially polymers, show remarkably lower 
safety risks that can be applied for specific therapeutic 
purposes. Their most specific feature is being capable of 
carrying large DNA molecules and being produced most 
cost-effectively and in large quantity (Dehshahri et al., 
2014). However, low transfection efficiency remains the 
major drawback of non-viral systems (Merdan, Kopecek, 
Kissel, 2002).
Polyallylamine (PAA) possessing a high density 
of primary amino groups (as free amino or as cationic 
ammonium salts) has recently attracted much attention as a 
non-viral gene delivery system (Nimesh, Kumar, Chandra, 
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2006; Boussif et al., 1999). Negatively charged DNA can 
be bound and packaged by PAA carrying a strong positive 
charge. However, PAA application as a gene delivery 
system has severely been restricted by cytotoxicity 
of PAA that is due to its strong polycationic character 
(Pathak et al., 2007). The lack of provision of endosomal 
escape resulting from the low buffering capacity of PAA 
is another disadvantage of this polymer (Pathak, Patnaik, 
Gupta, 2009). Numerous modifications have been carried 
out on this polymer to make it an effective and non-toxic 
carrier, including the preparation of nanocomplexes 
composed of PAA-dextran-DNA with an average size of 
about 150 nm, by Nimesh, Kumar, and Chandra (2006). 
Compared to the PAA-DNA nanoparticles, the evaluation 
of transfection efficiency of the prepared nanoparticles 
in HEK 293 cells showed an increase in the transfection 
efficiency and decrease in cytotoxicity. Moreover, in order 
to improve the endosomal release and enhance the gene 
transfer efficiency of the polymer, Pathak, Patnaik, and 
Gupta (2009) replaced primary amino groups of PAA (17 
kDa) with imidazolyl moieties. Recently, we modified 
PAA with bromoalkane derivatives (Oskuee et al., 2015a) 
and acrylate derivatives (Oskuee et al., 2015b). Better 
transfection activity and less cytotoxicity were observed 
in some of the prepared vectors. 
The present study aims at enhancing PAA transfection 
efficiency through replacing primary amino groups with 
cholesterol, reducing the polymer cytotoxicity, developing 
polymer hydrophobic interaction with the cell membrane, 
and maintaining the polymer buffering capacity. It is 
expected that as nanoparticles cross the cell membrane, 
vector release from the endosome becomes easier (through 
endosome membrane instability) and polymer toxicity 
decreases. 
MATERIALS AND METHODS
Materials
Dimethylformamide, cholesterol chloroformate and 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide] (MTT) were purchased from Sigma (USA). PAA 
(average MW 15 kDa) and PAA (average MW 65 kDa) 
were obtained from Polyscience Inc. (USA) and Aldrich 
(USA), respectively. 
Modification of PAA
For the preparation of PAA-cholesterol conjugates, 
both were dissolved separately in dimethylformamide. A 
solution of cholesteryl chloroformate was drop-wised to 
the stirring solution of PAA over 2 hours. The reaction was 
stirred for 24 additional hours at room temperature. The 
resulting solution was poured into a dialysis membrane 
(10 kDa cut-off dialysis tubing for derivate of PAA 15 kDa 
and 25 kDa cut-off dialysis tubing for derivate of PAA 65 
kDa) and dialyzed against double distilled water for 2 days 
to remove unreacted material. The aqueous solution was 
lyophilized to yield fluffy powders that were characterized 
by 1HNM (DMSO) spectroscopy using a Bruker Avance 
III-300 MHz NMR spectrometer (Bruker, Germany).
Determination of the degree of grafting percent 
by TNBS 
The primary amine content of modified PAA 
derivatives was determined using quantification of 
accessible primary amines through coupling with 
2,4,6-trinitrobenzene sulfonic acid (TNBS) (Snyder, 
Sobocinski, 1975). Briefly, 20 μl of freshly prepared 
aqueous TNBS solution (15 mg/ml) was added to the wells 
of a 96-well tray containing various amounts of modified 
PAA (dissolved in 600 μl of double distilled water). The 
mixtures were diluted with 200 μl of sodium bicarbonate 
buffer solution (0.8 M, pH 8.5) and the UV absorbance 
was measured at 405 nm.
Measurement of buffering capacity of modified 
PAA 
A solution of 0.4 mg/ml of each PAA derivative in 
double distilled water was prepared and adjusted to the pH 
of 12 using 1 M NaOH. Then, 5 μl aliquots of 1 M HCl 
were subsequently added until the pH was reduced to 2. 
The reciprocal slopes of graphs plotting pH versus the 
amount of HCl added were used to determine the buffering 
capacity of PAA derivatives.
Preparation of polyplexes
For preparation of polyplexes, different amounts of 
PAA derivatives were separately diluted into the HEPES 
buffered glucose solution (20 mM HEPES in 5% aqueous 
glucose solution) and mixed with pDNA at different carrier 
to pDNA weight ratios (C/P) ranging from 0.5:1 to 6:1. 
The mixture was incubated at room temperature for 30 
min before use.
Characterization of polyplexes
The mean size and zeta potential of nanocomplexes 
were determined using a particle size analyzer (Zetasizer 
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NanoZS, Malvern Instruments, UK). Condensation ability 
of cholesterol modified PAA was examined by the ethidium 
bromide (EtBr) test. This DNA-intercalating dye was used 
to examine the association of DNA with the modified 
polymer. The fluorescence intensity of this dye was 
measured at 510 nm (excitation wavelength) and 590 nm 
(emission wavelength) with a spectrofluorometer (Jasco, 
Japan). The fluorescence intensity was set to 100%. 
Equal amounts of the solution containing modified PAA 
were added stepwise to the pDNA–EtBr solution and 
the variation in fluorescence intensity was recorded. All 
measurements were done in triplicate.
Gene transfer studies
Neuro2A murine neuroblastoma cells (ATCC CCL-
131) were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with fetal bovine serum (10%), 
streptomycin (100 μg/ml), and penicillin (100 U/ml). Cells 
were seeded at a density of 1×104 cells per well in 96-well 
plates. Polyplexes were prepared in C/P ratios of 0.5, 2, 
4, and 6 and added to the cells. After 4 h incubation, the 
medium was removed and replaced with fresh medium. 
Cells were harvested 24 h post transfection and lysis buffer 
was added to each well. The percentage of transfected cells 
was determined using a fluorescent plate reader (Victor 
X5, Perkin- Elmer, USA). Green fluorescent protein (GFP) 
fluorescence was excited at 498 nm and emission was 
detected using a 535 nm band-pass filter. Polyethyleneimine 
(PEI) 25 kDa was used as positive control.
Cytotoxicity assay by MTT 
Cytotoxicity studies were carried out in Neuro2A 
cells using polymer/pDNA complexes. 1×104 cells per 
well were seeded in 96-well plates and treated after 24 h 
with the same amounts of polyplexes used for transfection 
experiment. After 4 h, the medium was replaced by 100 μl 
fresh culture medium. The metabolic activity of each well 
was determined after 24 h using MTT assay as follows: 
10 μl of a 5 mg/ml solution of MTT in sterile phosphate-
buffered saline buffer was added to each well. After 
incubation for 2 h at 37 °C, the medium was removed, 
100 μl of dimethyl sulfoxide added, and the samples 
further incubated at 37 °C for 30 min under constant 
shaking. Optical absorbance was measured at 590 nm 
(reference wavelength 630 nm) using a microplate reader 
(Statfax-2100; Awareness Technology, USA), and cell 
viability was expressed as a percent relative to untreated 
control cells. Values of metabolic activity are presented as 
mean ± SD of triplicates.
Statistical analysis
We used one-way ANOVA and the Tukey-Kramer 
test to analyze our data. Differences between means were 
statistically significant if the p-value was less than 0.05.
RESULTS
Cholesterol was grafted on 15 and 65 kDa PAA 
primary amines in different degrees of substitutions. The 
compositions of the modified polymers were confirmed 
by 1H NMR. As an example, the obtained data from 1H 
NMR (DMSO) spectrum of PAA15-Chol (15%) was: 
0.65 (s, 3H, CH3), 0.84 (d, 6H, J=6.0, 2×CH3), 0.91 
(d, 3H, J = 6.0, CH3), 0.94 (s, 3H, CH3), 0.84–1.53 (m, 
23H), 1.61–2.3 (m,7H), 3.2–3.6 (m, NCH2), 4.63–4.65 
(m, 1H), 5.27 (d, 1H). TNBS assay was done to determine 
the amount of primary amines of the modified polymers 
and the coverage of primary amines with cholesterol. As 
summarized in Table I, the degree of substitution was near 
to initial reaction feed. 
The results of acid-base titration studies were 
presented in Figure 1. This test was performed to assess 
the buffering capacity of modified polymers. Because 
of the relationship between the efficiency of polymer 
to facilitate endosome escape, this test was done on all 
samples. As indicated by results of Figure 1, cholesterol 
grafted PAA was led to a reduction of buffering capacity 
for both molecular weights of PAA.
TABLE I - Degree of primary amine substitution in cholesterol 
modified polyallylamine (PAA) (15 and 65 kDa) estimated by 
TNBS assay
Samples Initial reaction mole %
Calculated % of 
primary amine 
substitution by 
cholesterol
PAA15-Chol (5%) 5 3.2
PAA15-Chol (10%) 10 9.3
PAA15-Chol (15%) 15 16.2
PAA15-Chol (30%) 30 24.6
PAA15-Chol (50%) 50 52.2
PAA65-Chol (5%) 5 6.0
PAA65-Chol (10%) 10 13.2
PAA65-Chol (15%) 15 15.4
PAA65-Chol (30%) 30 29.1
PAA65-Chol (50%) 50 52.3
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The particle size and zeta potential of polyplexes 
were summarized in Table II. The particle sizes of all 
polyplexes prepared with modified cholesterol were 
found to be in the range of 125-530 nm. As the cholesterol 
content was increased, a concomitant increase in the size 
of the nanoparticles was observed. The vectors based on 
PAA 15 kDa had positive zeta potential. Only in the case 
of PAA with 50 % grafting, polyplex showed negative 
zeta-potential. All vectors based modified PAA 65 kDa 
had negative surface charge.
Both 15 and 65 kDa PAAs condensed the pDNA at 
C/P ratio of 0.5 (Figure 2). The interaction of DNA and 
synthetic polymers by substitution was decreased. The 
FIGURE 1 - Buffering capacity of A) polyallylamine (PAA) 15 
KDa derivatives, B) PAA 65 KDa derivatives.
TABLE II - Mean size, PDI, and zeta potential of polyplexes prepared by polyallylamine (PAA) (15 and 65 KDa) or cholesterol 
modified PAA /DNA (mean±SD, n=3)
Samples Mean Size (nm) PDI Zeta Potential(mV)
PAA15 161.6±9.7 0.39±0.07 19.2±3.0
PAA15-5% 255.2 0.368 25.1±1.9
PAA15-10% 124.0±7.8 0.34±0.08 24.6±1.1
PAA15-15% 308.1±28.3 0.40±0.04 28.8±3.4
PAA15-30% 322.1±24.9 0.51±0.06 34.5±0.5
PAA15-50% 320.8±20.3 0.58±0.15 -23.9±4.3
PAA65 75.4±20.9 0.43±0.16 13.3±1.4
PAA65-5% 533.0±23.6 0.64±0.03 -20.5±1.8
PAA65-10% 372.2±73.8 0.92±0.08 -13.9±2.0
PAA65-15% 344.2±21.5 0.64±0.10 -22.1±2.7
PAA65-30% 371.1±110.6 0.81±0.09 -27.5±0.7
PAA65-50% 414.5±14.6 0.88±0.12 -16.7±6.6
FIGURE 2 - The DNA condensation ability of polyallylamines 
(PAAs) (15 and 65 KDa) and modified PAAs. DNA condensation 
measured as a decrease in fluorescence of EtBr, A) PAA 15 KDa 
derivatives, B) PAA 65 KDa derivatives.
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complete condensation occurred at a higher C/P ratio by 
modification of PAA.
Gene transfer efficiency and cytotoxicity of 
pDNA polyplexes were evaluated in Neuro2A cells at 
four different C/P ratios as shown in Figures 3 and 4. 
Generally, transfection efficiency in vectors based PAA 
15 kDa increased and in vectors based PAA 65 kDa, 
modification of the polymer with cholesterol did not affect 
the transfection activity of the vector. The transfection 
activity of polyplexes composed of PAA 15 kDa was 
higher than PAA 65 kDa. The highest gene transfer ability 
belonged to PAA 15 kDa modified with 10% cholesterol 
at C/P ratio of 4. 
The effect of conjugation of PAA with cholesterol 
on cytotoxicity was examined on Neuro2A cells using 
the MTT assay. The cytotoxicity of PAA decreased 
remarkably by covering the amine groups of the polymer, 
especially in the higher C/P. It can be seen that the 
cytotoxicity of synthetic vectors in C/P 4 was less toxic 
than the unmodified PAA. It can be concluded that PAA 
toxicity may be alleviated by cholesterol modifications.
DISCUSSION
Gene therapy is a promising approach toward 
acquired or inherited disease treatment (Smith, 1999; 
Romano et al., 2000). To be applied in vitro, it is vital for 
gene delivery vectors to be efficient in transfection activity 
with low toxicity (Hasegawa, Hirashima, Nakanishi, 
2002). Some features including low immunogenicity and 
toxicity, ease of development, and lack of pathogenicity 
have particularly attracted more attention to non-viral 
vectors (Putnam, 2006; Li, Huang, 2006). However, 
in comparison to viral vectors, non-viral vector low 
transfection efficiency is introduced as the main drawback 
of these carriers (Tros-de-Ilarduya, Sun, Duzgunes, 2010).
Polyallylamine (PAA) has recently drawn much 
attention as a non-viral gene delivery system (Pathak et 
al., 2007; Oskuee et al., 2015b, Mahmoudi et al., 2014). 
Low buffering capacity and prevention of easy endosomal 
escape are introduced as the main disadvantages of this 
FIGURE 3 - Transfection activity of polyplexes prepared by 
polyallylamine (PAA) (15 and 65 KDa) or cholesterol modified 
PAA in Neuro2A cells. Complexes were formulated at three 
different C/P ratios, A) PAA 15 KDa derivatives, B) PAA 65 
KDa derivatives. Comparison was made between cholesterol 
modified PAAs and unmodified PAA, **: p<0.01, ***: p<0.001 
(mean±SD, n=3).
FIGURE 4 -  Cytotoxicity of polyplexes prepared by 
polyallylamine (PAA) (15 and 65 KDa) or cholesterol modified 
PAA at different C/P ratios, A) PAA 15 KDa derivatives, B) PAA 
65 KDa derivatives. Comparison was made between cholesterol 
modified PAAs and unmodified PAA, *: p<0.05, **: p<0.01, 
***: p<0.001 (mean±SD, n=3).
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polymer (Pathak, Patnaik, Gupta, 2009). If cationic 
polymers such as PAA are used without any chemical 
modification, they possess high cytotoxicity index 
(Gholami et al., 2014). Also, they usually require 
lysosomotropic agents or some modifications to improve 
endocytosis in order to achieve efficient gene transfer 
(Pathak et al., 2007). As an instance, Neu, Fischer, and 
Kissel (2005) argue that PAA interaction with endosome 
membranes improves and endosomal escape possibility 
increases if hydrophobic groups are used in the polymer 
structure. In the present study, primary amine groups of 
PAA with two molecular weights (15 and 65 kDa) were 
modified with cholesterol in five grafting percentages 
(5, 10, 15, 30, and 50) to enhance hydrophobicity. 
High transfection activity and low toxicity are the main 
justification criteria for cationic derivatives application 
(Hasegawa, Hirashima, Nakanishi, 2002; Hattori, Maitani, 
2007). Since cholesterol exists in the human body, its use 
in gene therapy is harmless. As indicated by the results of 
the previous study, polyethyleneimine (PEI)- cholesterol 
joined through a carbamate linkage are nontoxic and 
biodegradable (Kim et al., 2001). Although DNA and 
PAA have high aqueous solubility, due to lipophilic nature 
of cholesterol, the synthesized polymers showed lower 
aqueous solubility compared to PAA alone. As grafting 
percent increases, modified polymer aqueous solubility 
decreases. 
The ability of carriers in DNA condensation is 
assessed through the ethidium bromide test. As indicated 
by Oskuee et al. (2015a), the interaction between polymer 
positive charge and plasmid negative charge causes 
condensation. According to the results of the present study, 
unmodified PAA is more capable of DNA condensation, 
since primary amines of PAA are not surrounded by 
cholesterol. It is indicated that increasing grafting 
percent reduces modified polymer condensation ability, 
which is caused by the presence of voluminous amount 
of cholesterol. Therefore, DNA condensation happened 
through a higher C/P ratio.
Cellular uptake is heavily influenced by some factors 
such as surface charge and particle size. The effectiveness 
of transfection efficiency in polyplexes depends on particle 
size (Almofti et al., 2003; Zaric et al., 2004). In the present 
study, polyplexes in the 125 to 530 nm size range were 
formed by synthesized polymers. It is reported that as 
grafting percent increases, the size of polyplexes increases. 
According to the results of the previous study in the same 
field, compared to the unmodified PAA, the size of the 
polyplex increases as polymer hydrophobicity increases. 
Forrest, Koerber, and Pack (2003) suggest that reduced 
protonated ability makes binding polymers modified by 
DNA weaker, resulting in lower compact complexes. As 
reported by Rejman et al. (2004), particles with the size of 
500 nm enter through non-phagocytic paths. On the other 
hand, smaller than 200 nm particles enter through clathrin-
mediated endocytosis while 200–500 nm particles enter 
into the cell through the caveolae-mediated endocytosis 
path. Finally, as Khalil et al. (2006) argue, larger than 500 
nm particles entering through phagocytosis have low gene 
delivery efficiency. As far as the vectors of this study are 
concerned, particle size was in the 125 to 500 nm range 
making uptake occur through the caveolae-mediated 
endocytosis. Lysosomic decomposition, in this pathway, 
does not affect the polyplexes route. Therefore, Khalil et 
al. (2006) argue that this path is a useful gene delivery 
route. Moreover, Kim et al. (2006) reported that the 
binding of cholesterol to specific serum ligands increases 
the rate of polyplex entrance into the cell by ligand-
mediated endocytosis. Oskuee et al. (2008) emphasized 
that compact and positively charged particles can interact 
more effectively with lipid bilayer membranes resulting 
in more efficient transfection. The results of the study 
report that transfection efficiency increases in vector-based 
PAA15 kDa enhanced by increased grafting percentage. 
Vector lipophilicity increase caused by cholesterol addition 
resulting in enhanced vector cellular uptake may be the 
main reason for transfection efficiency increase. Vector 
suitable buffering capacity and favorable hydrophobic-
hydrophilic balance cause transfection efficiency variation 
after PAA modification with cholesterol (Oskuee et al., 
2015a, Oskuee et al., 2008). 
As indicated by the results of the present study, 
low grafting percentages made transfection rate increase 
while in 50% replaced carrier, no significant difference 
was evident between transfection efficiency of modified 
PAA and PAA15 kDa. Zintchenko et al. (2008) reported 
similar results for PEI modified with propionic acid or 
succinic acid. Thomas et al. (2005) argue that transfection 
ability is reduced if polycation positive charge is highly 
reduced while in previous studies, Oskuee et al. (2015b) 
concluded that polyplex transfection activity was not 
influenced by hydrophobic-modified PAA65 kDa. 
Additionally, according to the results of the present study 
regarding transfection efficiency, there is no significant 
difference between cholesterol modified PAA 65 kDa and 
the unmodified one. It should be noted that transfection is a 
cell-dependent procedure and the reason we employed the 
Neuro2a cell line is that it is hardly transfectable so if the 
newly synthesized vector could transfect it well, getting 
similar results with other cell lines is highly probable, 
however, other cell lines could be used in the transfection 
to make it possible to generalize the current data.
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Considering the limitations of measurement of 
the mitochondrial metabolic activity (MTT assay) in 
evaluating different aspects of toxicity raised by vectors, 
it was observed that in both molecular weights, polymer 
modification reduced viability significantly. As shown 
by viability profile, grafting percentage increase led to 
cytotoxicity reduction. Evidently, negatively charged 
cholesterol groups placement is the main reason for 
PAA toxicity reduction. According to Kim et al. (2001), 
the toxicity of polyplex embedded with PEI-cholesterol 
is reduced by cholesterol, and cell viability increase is 
remarkably affected by cholesterol percentage increase. 
PAA 65 kDa was more toxic than PAA 15 kDa. Hunter 
(2006) pointed out that polyplex with high positive charge 
results in interaction with the cell membrane causing 
damage to the cell. 
CONCLUSION
A series of vectors based on PAA15 kDa and 65 kDa 
were successfully synthesized. The results of transfection 
study showed that modified polymer composed of PAA 
(15 kDa) modified with cholesterol in 10% grafting is a 
suitable vector for gene delivery with low cytotoxicity.
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